The US Food and Drug Administration (FDA) has granted breakthrough device designation for Acrivon Therapeutics’ ACR-368 ...

On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...

Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations ...

In a bombshell announcement made last week, the Food and Drug Administration (FDA) said it will ban the use of FD&C Red No. 3 ...

A Food and Drug Administration project to promote diversity in clinical studies of cancer treatments was removed from the ...

Less than two months after an accelerated approval from the FDA, a drug combination featuring Pfizer’s Braftovi has turned in ...

New research from Emory University and international organizations could be a breakthrough in treating childhood brain cancer ...

The U.S. Food and Drug Administration has approved Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with ...

Earnings per share excluding some items surged to $2.09, Astra said Thursday, higher than the $2.04 estimated by analysts ...

A new drug delivery system shows promise for treating a rare, aggressive form of cancer affecting pregnant women and new ...

The ACR-368-tailored OncoSignature assay is being used to predict patients most likely to respond to ACR-368 in Acrivon’s ongoing, registrational-intent, multicenter Phase 2b trial of ACR-368 in ...

A small, early trial of a vaccine that mobilizes the immune system to battle advanced kidney cancers appears successf ...